{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T12:24:25Z","timestamp":1789647865509,"version":"4.0.0"},"reference-count":37,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T00:00:00Z","timestamp":1715126400000},"content-version":"unspecified","delay-in-days":7,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Northern Territory Department of Health","award":["Not Applicable"],"award-info":[{"award-number":["Not Applicable"]}]},{"name":"South Australia Department for Health and Wellbeing","award":["Not Applicable"],"award-info":[{"award-number":["Not Applicable"]}]},{"name":"Health Blood Borne Viruses and Sexually Transmissible Infections Research Program Grant","award":["GO5055"],"award-info":[{"award-number":["GO5055"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2024,3,28]]},"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      The effectiveness of antibiotics for treating gonococcal infections is compromised due to escalating antibiotic resistance; and the development of an effective gonococcal vaccine has been challenging. Emerging evidence suggests that the licensed meningococcal B (MenB) vaccine, 4CMenB is effective against gonococcal infections due to cross-reacting antibodies and 95% genetic homology between the two bacteria,\n                      <jats:italic>Neisseria meningitidis<\/jats:italic>\n                      and\n                      <jats:italic>Neisseria gonorrhoeae,<\/jats:italic>\n                      that cause the diseases. This project aims to undertake epidemiological and genomic surveillance to evaluate the long-term protection of the 4CMenB vaccine against gonococcal infections in the Northern Territory (NT) and South Australia (SA), and to determine the potential benefit of a booster vaccine doses to provide longer-term protection against gonococcal infections.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analyses<\/jats:title>\n                    <jats:p>\n                      This observational study will provide long-term evaluation results of the effectiveness of the 4CMenB vaccine against gonococcal infections at 4\u20137 years post 4CMenB programme implementation. Routine notifiable disease notifications will be the basis for assessing the impact of the vaccine on gonococcal infections. Pathology laboratories will provide data on the number and percentage of\n                      <jats:italic>N. gonorrhoeae<\/jats:italic>\n                      positive tests relative to all tests administered and will coordinate molecular sequencing for isolates. Genome sequencing results will be provided by SA Pathology and Territory Pathology\/New South Wales Health Pathology, and linked with notification data by SA Health and NT Health. There are limitations in observational studies including the potential for confounding. Confounders will be analysed separately for each outcome\/comparison.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The protocol and all study documents have been reviewed and approved by the SA Department for Health and Well-being Human Research Ethics Committee (HREC\/2022\/HRE00308), and the evaluation will commence in the NT on receipt of approval from the NT Health and Menzies School of Health Research Human Research Ethics Committee. Results will be published in peer-reviewed journals and presented at scientific meetings and public forums.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2023-079144","type":"journal-article","created":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T13:06:16Z","timestamp":1715173576000},"page":"e079144","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Comprehensive observational study evaluating the enduring effectiveness of 4CMenB, the meningococcal B vaccine against gonococcal infections in the Northern Territory and South Australia, Australia: study protocol"],"prefix":"10.1136","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct04415424","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04350138","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04597424","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05766904","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04722003","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05294588","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04398849","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04597424","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2521-5166","authenticated-orcid":false,"given":"Helen","family":"Marshall","sequence":"first","affiliation":[{"name":"Vaccinology and Immunology Research Trials Unit, Women\u2019s and Children\u2019s Hospital, Adelaide, South Australia, Australia"},{"name":"Adelaide Medical School, The University of Adelaide, Adelaide, South Australia, Australia"},{"name":"Robinson Research Institute, The University of Adelaide, Adelaide, South Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Ward","sequence":"additional","affiliation":[{"name":"Poche Centre, The University of Queensland, Brisbane, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Wang","sequence":"additional","affiliation":[{"name":"Vaccinology and Immunology Research Trials Unit, Women\u2019s and Children\u2019s Hospital, Adelaide, South Australia, Australia"},{"name":"Adelaide Medical School, The University of Adelaide, Adelaide, South Australia, Australia"},{"name":"Robinson Research Institute, The University of Adelaide, Adelaide, South Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prabha","family":"Andraweera","sequence":"additional","affiliation":[{"name":"Vaccinology and Immunology Research Trials Unit, Women\u2019s and Children\u2019s Hospital, Adelaide, South Australia, Australia"},{"name":"Adelaide Medical School, The University of Adelaide, Adelaide, South Australia, Australia"},{"name":"Robinson Research Institute, The University of Adelaide, Adelaide, South Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6490-7707","authenticated-orcid":false,"given":"Mark","family":"McMillan","sequence":"additional","affiliation":[{"name":"Vaccinology and Immunology Research Trials Unit, Women\u2019s and Children\u2019s Hospital, Adelaide, South Australia, Australia"},{"name":"Adelaide Medical School, The University of Adelaide, Adelaide, South Australia, Australia"},{"name":"Robinson Research Institute, The University of Adelaide, Adelaide, South Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Flood","sequence":"additional","affiliation":[{"name":"Communicable Disease Control Branch, Department for Health and Wellbeing, Government of South Australia, Adelaide, South Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Bell","sequence":"additional","affiliation":[{"name":"Communicable Disease Control Branch, Department for Health and Wellbeing, Government of South Australia, Adelaide, South Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Sisnowski","sequence":"additional","affiliation":[{"name":"Communicable Disease Control Branch, Department for Health and Wellbeing, Government of South Australia, Adelaide, South Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicki","family":"Krause","sequence":"additional","affiliation":[{"name":"Centre for Disease Control & Environmental Health, NT Health, Northern Territory Government, Darwin, Northern Territory, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalind","family":"Webby","sequence":"additional","affiliation":[{"name":"Centre for Disease Control & Environmental Health, NT Health, Northern Territory Government, Darwin, Northern Territory, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Childs","sequence":"additional","affiliation":[{"name":"Immunisation and Notifiable Diseases, NT Health, Northern Territory Government, Darwin, Northern Territory, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoji","family":"Gunathilake","sequence":"additional","affiliation":[{"name":"Centre for Disease Control & Environmental Health, NT Health, Northern Territory Government, Darwin, Northern Territory, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Egoroff","sequence":"additional","affiliation":[{"name":"Centre for Disease Control & Environmental Health, NT Health, Northern Territory Government, Darwin, Northern Territory, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lex","family":"Leong","sequence":"additional","affiliation":[{"name":"SA Pathology, SA Health, Government of South Australia, Adelaide, South Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Lawrence","sequence":"additional","affiliation":[{"name":"SA Pathology, SA Health, Government of South Australia, Adelaide, South Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"Baird","sequence":"additional","affiliation":[{"name":"Territory Pathology, NT Health, Northern Territory Government, Darwin, Northern Territory, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Freeman","sequence":"additional","affiliation":[{"name":"Territory Pathology, NT Health, Northern Territory Government, Darwin, Northern Territory, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Menouhos","sequence":"additional","affiliation":[{"name":"Territory Pathology, NT Health, Northern Territory Government, Darwin, Northern Territory, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M","family":"Whiley","sequence":"additional","affiliation":[{"name":"UQ Centre for Clinical Research, The University of Queensland and Pathology Queensland, Brisbane, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Karnon","sequence":"additional","affiliation":[{"name":"College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"van Hal","sequence":"additional","affiliation":[{"name":"Microbiology, NSW Health Pathology, Sydney, New South Wales, Australia"},{"name":"The University of Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica M","family":"Lahra","sequence":"additional","affiliation":[{"name":"Microbiology, NSW Health Pathology, Sydney, New South Wales, Australia"},{"name":"The University of New South Wales, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,5,8]]},"reference":[{"key":"2025121602575514000_14.5.e079144.1","first-page":"12","article-title":"Infertility: a global perspective. The role of pelvic infection","volume":"1994","author":"Sciarra","year":"1994","journal-title":"ORGYN"},{"key":"2025121602575514000_14.5.e079144.2","doi-asserted-by":"crossref","unstructured":"Soong TR , Granter SR , Haefner HK , et al . Chapter 4 - infectious disorders of the lower genital tract. In: Crum CP , Nucci MR , Howitt BE , et al , eds. Diagnostic Gynecologic and Obstetric Pathology. 3rd edn. Philadelphia: Elsevier, 2018: 62\u2013100.","DOI":"10.1016\/B978-0-323-44732-4.00004-2"},{"key":"2025121602575514000_14.5.e079144.3","doi-asserted-by":"crossref","unstructured":"Lahra MM , Hogan TR , Armstrong BH . Australian gonococcal surveillance programme annual report, 2021. Commun Dis Intell (2018) 2018;46. doi:10.33321\/cdi.2022.46.52","DOI":"10.33321\/cdi.2022.46.52"},{"key":"2025121602575514000_14.5.e079144.4","unstructured":"Surveillance update for Notifiable Stis and Bbvs in the NT. Northern Territory Health Northern Territory: Centre for Disease Control, Public Health Unit-Top End Health Service; 2021."},{"key":"2025121602575514000_14.5.e079144.5","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3390\/vaccines10020309","article-title":"An observational study to assess the effectiveness of 4Cmenb against meningococcal disease and carriage and gonorrhea in adolescents in the Northern territory, Australia-study protocol","volume":"10","author":"Marshall","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"2025121602575514000_14.5.e079144.6","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3390\/antibiotics8040191","article-title":"Trends in antimicrobial resistance patterns in neisseria gonorrhoeae in Australia and New Zealand: a meta-analysis and systematic review","volume":"8","author":"Fletcher-Lartey","year":"2019","journal-title":"Antibiotics (Basel)"},{"key":"2025121602575514000_14.5.e079144.7","doi-asserted-by":"crossref","unstructured":"Lyu Y , Choong A , Chow EPF , et al . Vaccine value profile for neisseria gonorrhoeae. Vaccine 2023. doi:10.1016\/j.vaccine.2023.01.053","DOI":"10.1016\/j.vaccine.2023.01.053"},{"key":"2025121602575514000_14.5.e079144.8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31449-6"},{"key":"2025121602575514000_14.5.e079144.9","doi-asserted-by":"crossref","first-page":"B87","DOI":"10.1016\/j.vaccine.2012.01.033","article-title":"The new multicomponent vaccine against meningococcal serogroup B, 4Cmenb: immunological, functional and structural characterization of the antigens","volume":"30 Suppl 2","author":"Serruto","year":"2012","journal-title":"Vaccine"},{"key":"2025121602575514000_14.5.e079144.10","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1093\/cid\/ciy1061","article-title":"The Serogroup B meningococcal vaccine bexsero elicits antibodies to neisseria gonorrhoeae","volume":"69","author":"Semchenko","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2025121602575514000_14.5.e079144.11","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ijid.2019.05.019","article-title":"Potential benefits of using a multicomponent vaccine for prevention of serogroup B meningococcal disease","volume":"85","author":"Watson","year":"2019","journal-title":"Int J Infect Dis"},{"key":"2025121602575514000_14.5.e079144.12","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S1473-3099(21)00812-4","article-title":"Effectiveness of a serogroup B outer membrane vesicle meningococcal vaccine against gonorrhoea: a retrospective observational study","volume":"22","author":"Abara","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"2025121602575514000_14.5.e079144.13","doi-asserted-by":"crossref","first-page":"e1341","DOI":"10.1093\/cid\/ciac436","article-title":"Prevention of neisseria gonorrhoeae with meningococcal B vaccine: a matched cohort study in Southern California","volume":"76","author":"Bruxvoort","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2025121602575514000_14.5.e079144.14","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofx180.001"},{"key":"2025121602575514000_14.5.e079144.15","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S1473-3099(21)00754-4","article-title":"Effectiveness and impact of the 4Cmenb vaccine against invasive serogroup B meningococcal disease and gonorrhoea in an infant, child, and adolescent programme: an observational cohort and case-control study","volume":"22","author":"Wang","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"2025121602575514000_14.5.e079144.16","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/OLQ.0000000000001771","article-title":"Meningococcus B vaccination effectiveness against neisseria gonorrhoeae infection in people living with HIV: a case-control study","volume":"50","author":"Raccagni","year":"2023","journal-title":"Sex Transm Dis"},{"key":"2025121602575514000_14.5.e079144.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.07.015"},{"key":"2025121602575514000_14.5.e079144.18","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jinf.2023.05.021","article-title":"4Cmenb sustained vaccine effectiveness against invasive meningococcal B disease and gonorrhoea at three years post programme implementation","volume":"87","author":"Wang","year":"2023","journal-title":"J Infect"},{"key":"2025121602575514000_14.5.e079144.19","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.20.11109"},{"key":"2025121602575514000_14.5.e079144.20","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1093\/cid\/ciy1061","article-title":"The serogroup B meningococcal vaccine bexsero elicits antibodies to neisseria gonorrhoeae","volume":"69","author":"Semchenko","year":"2019","journal-title":"Clinical Infectious Diseases"},{"key":"2025121602575514000_14.5.e079144.21","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-020988","article-title":"B part of it protocol: a cluster randomised controlled trial to assess the impact of 4Cmenb vaccine on pharyngeal carriage of neisseria meningitidis in adolescents","volume":"8","author":"Marshall","year":"2018","journal-title":"BMJ Open"},{"key":"2025121602575514000_14.5.e079144.22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMa1900236"},{"key":"2025121602575514000_14.5.e079144.23","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.e7586","article-title":"SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials","volume":"346","author":"Chan","year":"2013","journal-title":"BMJ"},{"key":"2025121602575514000_14.5.e079144.24","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1177\/0956462416681940","article-title":"Repeat infection with neisseria gonorrhoeae among active duty U.S. Army personnel: a population-based case-series study","volume":"28","author":"Bautista","year":"2017","journal-title":"Int J STD AIDS"},{"key":"2025121602575514000_14.5.e079144.25","unstructured":"Communicable Diseases Network Australia (CDNA) . Gonococcal infection-CDNA national guidelines for public health units. In: Department of Health and Aged Care: Commonwealth of Australia. 2019."},{"key":"2025121602575514000_14.5.e079144.26","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyw314"},{"key":"2025121602575514000_14.5.e079144.27","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jinf.2018.11.009","article-title":"Varicella vaccine effectiveness over 10 years in Australia; moderate protection from 1-dose program","volume":"78","author":"Quinn","year":"2019","journal-title":"J Infect"},{"key":"2025121602575514000_14.5.e079144.28","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyac013"},{"key":"2025121602575514000_14.5.e079144.29","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-023-16169-7"},{"key":"2025121602575514000_14.5.e079144.30","doi-asserted-by":"crossref","unstructured":"Hanquet G , Christensen H , Agnew E , et al . A Quadrivalent vaccine against Serogroup B Meningococcal disease: a cost-effectiveness study. Health Technology Assessment (HTA); 2014.","DOI":"10.57598\/R231C"},{"key":"2025121602575514000_14.5.e079144.31","doi-asserted-by":"publisher","DOI":"10.4161\/hv.36221"},{"key":"2025121602575514000_14.5.e079144.32","doi-asserted-by":"crossref","DOI":"10.1186\/s12962-018-0087-x","article-title":"Incorporating economies of scale in the cost estimation in economic evaluation of PCV and HPV vaccination programmes in the Philippines: a game changer","volume":"16","author":"Suwanthawornkul","year":"2018","journal-title":"Cost Eff Resour Alloc"},{"key":"2025121602575514000_14.5.e079144.33","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1007\/s40273-020-00942-2","article-title":"Perspective and costing in cost-effectiveness analysis, 1974-2018","volume":"38","author":"Kim","year":"2020","journal-title":"Pharmacoeconomics"},{"key":"2025121602575514000_14.5.e079144.34","unstructured":"Drummond M . Methods for the Economic Evaluation of Health Care Programmes. 4th edn. Oxford, United Kingdom\u202f; New York, NY, USA: Oxford University Press, 2015."},{"key":"2025121602575514000_14.5.e079144.35","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1186\/s12889-023-15516-y","article-title":"An open-label randomised controlled trial evaluating the efficacy of a meningococcal serogroup B (4Cmenb) vaccine on neisseria gonorrhoeae infection in gay and bisexual men: the mengo study protocol","volume":"23","author":"Thng","year":"2023","journal-title":"BMC Public Health"},{"key":"2025121602575514000_14.5.e079144.36","unstructured":"Molina J , Bercot B , Assoumou L , et al . ANRS 174 DOXYVAC: an open-label randomized trial to prevent Stis in MSM on prep. 30th Conference on Retroviruses and Opportunistic Infections (CROI); 2023:2\u201322."},{"key":"2025121602575514000_14.5.e079144.37","unstructured":"Molina J , Bercot B , Assoumou L , et al . ANRS 174 DOXYVAC: an open-label randomized trial to prevent Stis in MSM on prep. 31st Conference on Retroviruses and Opportunistic Infections (CROI); 2024"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2023-079144","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T10:58:05Z","timestamp":1765882685000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2023-079144"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":37,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,5,8]]},"published-print":{"date-parts":[[2024,5]]}},"alternative-id":["10.1136\/bmjopen-2023-079144"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2023-079144","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5]]}}}